The present work provides valuable insights into the antibacterial and antibiofilm activities of selected EOs against MDR- NG

The gap

Evidence profile

Sourced from the future work and limitations of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 2 journals. Those papers have been cited 61 times in total.

Supporting evidence — 3 representative gaps

• Essential Oils as Antimicrobial Agents Against WHO Priority Bacterial Pathogens: A Strategic Review of In Vitro Clinical Efficacy, Innovations and Research Gaps (2025) · Antibiotics · cited 36× · doi

  EOs represent a paradigm shift in antimicrobial therapy due to their multi-target mechanisms of action, which differ fundamentally from those of conventional single-mol- ecule antibiotics. Their ability to simultaneously disrupt bacterial cell membranes, inhibit biofilm formation, interfere with QS, and modulate efflux pump activity positions them as particularly valuable weapons against AMR. The mechanistic diversity of EOs, exem- plified by the efficacy of cinnamon, clove, oregano, and tea tree oils against WHO-priority pathogens such as MRSA, carbapenem-resistant K. pneumoniae, A. baumannii, and P. aeru- ginosa, demonstrates their potential to address urgent public health needs where conven- tional antibiotics have failed. The synergistic potential of EOs with existing antibiotics emerges as one of their most clinically relevant attributes. This combinatorial approach not only enhances the efficacy of established antimicrobial agents but also provides a pathway to revive antibiotics that Antibiotics 2025, 14, 1250 38 of 57 have lost effectiveness due to the development of resistance. The ability of EOs to inhibit β-lactamases, downregulate efflux pumps, and modulate bacterial gene expression pro- vides multiple avenues for overcoming established resistance mechanisms. However, the path to clinical implementation faces significant obstacles. The inherent variability in EO composition presents a fundamental challenge to standardization and reproducibility, indicating the need for robust quality control measures, standardized ex- traction protocols, and chemotype selection strategies. While nanoencapsulation technol- ogies, including chitosan nanoparticles and liposomal formulations, offer promising solu- tions to enhance stability, bioavailability, and targeted delivery, the practical hurdles of scaling up production, managing costs, and navigating regulatory approval for nanofor- mulations remain substantial. The current evidence base, while compelling, is heavily weighted toward in vitro and ex vivo studies, and well-designed clinical trials to validate efficacy and safety in human subjects are essential for future translation of EOs potential into clinical practice. The lim- ited availability of in vivo models and clinical data represents a significant gap that needs to be bridged before EOs can be considered viable therapeutic alternatives. Additionally, while EOs are generally considered less prone to resistance development due to their multi-target nature, emerging evidence suggests that bacterial adaptation mechanisms, such as efflux pump upregulation, may still pose risks that warrant careful monitoring. Should EOs value be preserved as alternatives to conventional antibiotics, such adapta- tion and probable resistance emergence are potential venues for ongoing investigation. The integration of artificial intelligence and machine learning approaches, as demon- strated by

  generalfuture work
  Keywords: antibiotics potential resistance clinical mechanisms bacterial efflux efficacy antimicrobial multi target conventional ability inhibit modulate
• Infective Endocarditis by Biofilm-Producing Methicillin-Resistant Staphylococcus aureus—Pathogenesis, Diagnosis, and Management (2024) · Antibiotics · cited 25× · doi

  MRSA-associated IE is a complex and evolving clinical problem, with biofilm-mediated resistance posing persistent challenges in both diagnosis and treatment. While current therapeutic regimens are essential, they often require supplementation with surgical inter- Antibiotics 2024, 13, 1132 16 of 22 vention, and emerging targeted strategies may offer important additional tools to address the limitations imposed by biofilms. The integration of novel therapies alongside estab- lished clinical practices offers a promising future for improving patient outcomes and reducing the high morbidity and mortality associated with MRSA IE. Continued research and innovation in diagnostics and therapeutics are essential for combating MRSA IE, one of the most difficult infections in modern medicine. Author Contributions: Concept and design: all authors. Acquisition, analysis, or interpretation of data: A.K., H.K., S.G., M.S., C.T., B.W.S. and M.P. Drafting of the manuscript: A.K., H.K., M.S., S.G., C.T., B.W.S. and M.P. Critical revision of the manuscript for important intellectual content: A.K., H.K., M.S., S.G., B.W.S., C.T. and M.P. Administrative, technical, or material support: A.K. and S.G. Supervision: A.K., H.K. and S.G. None of the authors have any financial disclosures or other conflicting relationships. The authors fully acknowledge and comply with the Journal’s Conflict of Interest policy. All authors have read and agreed to the published version of the manuscript. Funding: This research received no external funding. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: No new data were created or analyzed in this study. Acknowledgments: We would like to thank Naomi Hein, from the Harvard Medical School, for editing this manuscript. Conflicts of Interest: The authors declare no conflicts of interest.

  generalfuture work
  Keywords: authors manuscript mrsa interest statement associated clinical essential important funding applicable conflicts complex evolving problem
• Antimicrobial, Bactericidal and Antibiofilm Activity of Selected Essential Oils against Multidrug-resistant Clinical Isolates of Neisseria gonorrhoeae (2026) · Journal of Pure and Applied Microbiology · doi

  Although the present work provides valuable insights into the antibacterial and antibiofilm activities of selected EOs against MDR- NG, the study has some limitations. The findings are based solely on in vitro experiments, and in vivo or clinical validation was not performed. Additionally, the cytotoxicity and safety profiles of the tested essential oils were not evaluated. Therefore, further investigations involving in vivo studies and clinical validation are required to confirm their safety and therapeutic potential.

  generallimitationsevidence 5/5
  Keywords: vivo clinical validation safety present provides valuable insights antibacterial antibiofilm activities selected against limitations based

Questions about this gap